TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00008138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debulking surgery
Description: exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
Study: NCT04053543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: (10-nitro-9(E)-octadec-9enoic acid)
Study: NCT00555828

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: 25 M allogeneic MPCs by transendocardial injection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard-of-care treatment with NOGA® mapping and staged injections.
Description: Standard-of-care treatment with NOGA® mapping and staged injections.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: 75 M allogeneic MPCs by transendocardial injection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard-of-care treatment with NOGA® mapping and staged injections.
Description: Standard-of-care treatment with NOGA® mapping and staged injections.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: 150 M allogeneic MPCs by transendocardial injection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard-of-care treatment with NOGA® mapping and staged injections.
Description: Standard-of-care treatment with NOGA® mapping and staged injections.
Study: NCT03799718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NurOwn (MSC-NTF cells)
Description: Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Study: NCT02262039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valveless recirculating insufflation (VTI)
Description: 10 mmHg target pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pressure
Description: 15 mmHg target pressure
Study: NCT00528346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training using fMRI
Description: Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Some participants will see simulated data that does not come from their own brains.
Study: NCT05270538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane
Description: The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
Study: NCT03751995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in.
Study: NCT02292303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc-enriched yeast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc references

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc references
Study: NCT00258427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
Study: NCT01803516

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
Study: NCT01456078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TATE
Description: 177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy.
Study: NCT02864628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B
Study: NCT00258427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 35 mg/m\^2 intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 35 mg/m\^2 intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 35 mg/m\^2 intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 35 mg/m\^2 intravenously (IV) on Days -5 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
Study: NCT02864628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B
Study: NCT00258427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
Study: NCT02864628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline
Study: NCT01559519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
Study: NCT02551055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion
Study: NCT00430300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-432,097
Description: Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing 100% lactose administered BID using an atomizer device
Study: NCT01597752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control
Description: Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study: NCT00775242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol and Progesterone
Description: Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol and Progesterone
Description: Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
Study: NCT04021667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
Study: NCT03059264

Intervention type: OTHER
Intervention: Natural history
Description: Longitudinal disease progression

Intervention type: OTHER
Intervention: Natural history
Description: Longitudinal disease progression
Study: NCT03245593

Intervention type: OTHER
Intervention: Shared-decision making process
Description: Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available

Intervention type: OTHER
Intervention: standard care
Description: Care of patients according to standard practice of managing patients with bipolar disorder
Study: NCT04361318

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus Nitazoxanide
Description: Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
Study: NCT02677974

Intervention type: DEVICE
Intervention: On-X Aortic Heart Valve replacement
Description: Aortic valve replacement with low dose warfarin
Study: NCT01696136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac ablation for Atrial Fibrillation
Description: Cardiac ablation for Atrial Fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac ablation for Atrial Fibrillation
Description: Cardiac ablation for Atrial Fibrillation
Study: NCT01082887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIL-Ad-INFg
Description: After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
Study: NCT02375217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: half dose
Study: NCT00529048

Intervention type: OTHER
Intervention: Isoglycemic clamp
Description: I.v. glucose infusion initiating the glucose responds curves from the OGTT
Study: NCT02375217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: full dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: IV = 50mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrrolate
Study: NCT00529048

Intervention type: OTHER
Intervention: Isoglycemic clamp
Description: I.v. glucose infusion initiating the glucose responds curves from the OGTT

Intervention type: OTHER
Intervention: Gastric emptying rate
Description: Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
Study: NCT01537133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
Study: NCT00529048

Intervention type: OTHER
Intervention: Gastric emptying rate
Description: Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
Study: NCT00833690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
Study: NCT01537133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry Powder Inhaler: Placebo
Study: NCT03640455

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
Study: NCT05500768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypothermic compression bandage
Description: a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional compression bandage
Description: a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
Study: NCT03258879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified CSE
Description: MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: DPE group: Dural puncture performed, but no medication will be injected intrathecally.
Study: NCT00746291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 min walk test, Step climbing
Description: walking for 6 minute and climbing steps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 min walk test, Step climbing
Description: walking for 6 minute and climbing steps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 min walk test, Step climbing
Description: walking for 6 minute and climbing steps
Study: NCT01353248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, 30 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir
Description: capsule, 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir
Description: capsule, 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, 90 mg QD
Study: NCT00258427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
Study: NCT03775018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane blockade
Description: Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesia
Description: Acetaminophen 1g/6h iv will be administered